Updates are available Correction dated 2024-01-10

Article History

Received: 21 November 2019

Revised: 30 January 2020

Accepted: 3 February 2020

First Online: 14 February 2020

Change Date: 10 January 2024

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1038/s41375-023-02133-2

Compliance with ethical standards

:

: GL has received honoraria from AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Gilead, Hexal, Janssen, MorphoSys, NanoString, and Roche, has participated in a consulting or advisory role for Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Gilead, Hexal, Janssen, MorphoSys, NanoString, Novartis, and Roche, has been on a speaker’s bureau for Bayer, Celgene, Gilead, Janssen, and Roche, has received research funding from AstraZeneca, Bayer, Celgene, Gilead, Janssen, and Roche, and has had travel, accommodation, and expenses reimbursed by Bayer, Celgene, Gilead, Hexal, Janssen, and Roche. EH has participated in a consulting or advisory role for Bristol-Myers Squibb, Celgene, and Janssen, has been on a speaker’s bureau for Bristol-Myers Squibb, Janssen, and Roche, has received research funding from Bristol-Myers Squibb, Celgene, Merck Serono, and Merck Sharp & Dohme, and has had travel, accommodation, and expenses reimbursed by Bristol-Myers Squibb, Roche, and Takeda. CH has received honoraria from Celgene, Gilead, Janssen, Novartis, Roche, and Takeda, has participated in a consulting or advisory role for Celgene, Gilead, Janssen, Roche, and Takeda, and has had travel, accommodation, and expenses reimbursed by Celgene and Roche. KA has received honoraria from Takeda, has participated in a consulting or advisory role for Celgene, Gilead, Roche, and Takeda, has received research funding from Cell Medica, Gilead, Infinity, Merck, and Pharmacyclics, has had travel, accommodation, and expenses reimbursed by Celgene, Gilead, Roche, and Takeda, and is supported by the UCLH/UCL Biomedical Research Centre. GC has received research funding from Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb, Hutchison, Incyte, Merck Serono, and Novartis. WS is employed by Bayer HealthCare Pharmaceuticals. IG was employed by Bayer HealthCare Pharmaceuticals. SL is employed by, and has stock or other ownership at, Bayer AG. FH is employed by Bayer AG and has stock or other ownership at Bayer AG, Evotec AG, Gilead, Hologen AG, Medigene AG, and 4SC AG. PP is employed by, and has stock or other ownership at, Bayer AG. GB is employed by Bayer AG. CP is employed by, has stock at, and has co-authored patents at Bayer HealthCare Pharmaceuticals. VB is employed by Bayer HealthCare Pharmaceuticals. BHC is employed by Bayer HealthCare Pharmaceuticals. GS has received honoraria from Acerta, Amgen, Bristol-Myers Squibb, Celgene, Gilead, Janssen, Merck, MorphoSys, Novartis, Pfizer, Roche, and Servier, has participated in a consulting or advisory role for Amgen, Celgene, Gilead, Merck, Novartis, Pfizer, Roche, and Servier, has received research funding from Acerta, Amgen, Bristol-Myers Squibb, Celgene, Gilead, Janssen, Merck, MorphoSys, Novartis, Pfizer, Roche, Sanofi, Servier, and Takeda, and has had travel, accommodation, and expenses reimbursed by Roche and Sanofi. GV, STL, DSH, and JH declare no competing financial interests.